Dataset Information

A link between lipid metabolism and epithelial-mesenchymal transition provides a target for colon cancer therapy.

ABSTRACT: The alterations in carbohydrate metabolism that fuel tumor growth have been extensively studied. However, other metabolic pathways involved in malignant progression, demand further understanding. Here we describe a metabolic acyl-CoA synthetase/stearoyl-CoA desaturase ACSL/SCD network causing an epithelial-mesenchymal transition (EMT) program that promotes migration and invasion of colon cancer cells. The mesenchymal phenotype produced upon overexpression of these enzymes is reverted through reactivation of AMPK signaling. Furthermore, this network expression correlates with poorer clinical outcome of stage-II colon cancer patients. Finally, combined treatment with chemical inhibitors of ACSL/SCD selectively decreases cancer cell viability without reducing normal cells viability. Thus, ACSL/SCD network stimulates colon cancer progression through conferring increased energetic capacity and invasive and migratory properties to cancer cells, and might represent a new therapeutic opportunity for colon cancer treatment.

SUBMITTER: Sanchez-Martinez R

PROVIDER: S-EPMC4770732 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A link between lipid metabolism and epithelial-mesenchymal transition provides a target for colon cancer therapy.

Sánchez-Martínez Ruth R Cruz-Gil Silvia S Gómez de Cedrón Marta M Álvarez-Fernández Mónica M Vargas Teodoro T Molina Susana S García Belén B Herranz Jesús J Moreno-Rubio Juan J Reglero Guillermo G Pérez-Moreno Mirna M Feliu Jaime J Malumbres Marcos M Ramírez de Molina Ana A

Oncotarget 20151101 36

The alterations in carbohydrate metabolism that fuel tumor growth have been extensively studied. However, other metabolic pathways involved in malignant progression, demand further understanding. Here we describe a metabolic acyl-CoA synthetase/stearoyl-CoA desaturase ACSL/SCD network causing an epithelial-mesenchymal transition (EMT) program that promotes migration and invasion of colon cancer cells. The mesenchymal phenotype produced upon overexpression of these enzymes is reverted through rea ...[more]

PMID: 26451612

Similar Datasets

Project description:Aberrant T-cell factor (TCF) transcription is implicated in the majority of colorectal cancers (CRCs). TCF transcription induces epithelial-mesenchymal transition (EMT), promoting a tumor-initiating cell (TIC) phenotype characterized by increased proliferation, multidrug resistance (MDR), invasion and metastasis. The data presented herein characterize topoisomerase II? (TopoII?) as a required component of TCF transcription promoting EMT. Using chromatin immunoprecipitation (ChIP) and protein co-immunoprecipitation (co-IP) studies, we show that TopoII? forms protein-protein interactions with ?-catentin and TCF4 and interacts with Wnt response elements (WREs) and promoters of direct target genes of TCF transcription, including: MYC, vimentin, AXIN2 and LEF1. Moreover, both TopoII? and TCF4 ChIP with the N-cadherin promoter, which is a new discovery indicating that TCF transcription may directly regulate N-cadherin expression. TopoII? N-terminal ATP-competitive inhibitors, exemplified by the marine alkaloid neoamphimedine (neo), block TCF activity in vitro and in vivo. Neo effectively inhibits TopoII? and TCF4 from binding WREs/promoter sites, whereas protein-protein interactions remain intact. Neo inhibition of TopoII?-dependent TCF transcription also correlates with significant antitumor effects in vitro and in vivo, including the reversion of EMT, the loss of TIC-mediated clonogenic colony formation, and the loss of cell motility and invasion. Interestingly, non-ATP-competitive inhibitors of TopoII?, etoposide and merbarone, were ineffective at preventing TopoII?-dependent TCF transcription. Thus, we propose that TopoII? participation in TCF transcription may convey a mechanism of MDR to conventional TopoII? inhibitors. However, our results indicate that TopoII? N-terminal ATP-binding sites remain conserved and available for drug targeting. This article defines a new strategy for targeted inhibition of TCF transcription that may lead to effective therapies for the treatment of CRC and potentially other Wnt-dependent cancers.

Dataset Information

A link between lipid metabolism and epithelial-mesenchymal transition provides a target for colon cancer therapy.

Publications

A link between lipid metabolism and epithelial-mesenchymal transition provides a target for colon cancer therapy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets